Sukyong Yoon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sukyong Yoon has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Choon Ok Kim
Department of Clinical Pharmacology, Severance Hospital, Yonsei University Health System, Seoul 03722, Republic of Korea
4 shared publications - Min Soo Park
Department of Clinical Pharmacology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
4 shared publications - Hyeonsoo Park
Department of Clinical Pharmacology, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Korea
3 shared publications - EunSil Oh
Department of Clinical Pharmacology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
2 shared publications - Woo Yul Lee
Department of Pharmacology, Yonsei University College of Medicine, Seoul 03722, Korea
2 shared publications - Yeji Lim
Clinical Development and Medical Division, Yuhan Corporation, Seoul 06927, Korea
2 shared publications
Latest Publications
- Open Access
- 27 February 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (3) , 334
Pharmacokinetic Modeling of Bepotastine for Determination of Optimal Dosage Regimen in Pediatric Patients with Allergic Rhinitis or Urticaria
Bepotastine, a second-generation antihistamine for allergic rhinitis and urticaria, is widely used in all age groups but lacks appropriate dosing guidelines for pediatric patients, leading to off-label prescriptions. We conducted this study to propose an optimal dosing regimen for pediatric patients based on population pharmacokinetic (popPK) and physiologically based pharmacokinetic (PBPK) models using data from two previous trials. A popPK model was built using NONMEM software. A one-compartment model with first-order absorption and absorption lag time described our data well, with body weight incorporated as the only covariate. A PBPK model was developed using PK-Sim software version 10, and the model well predicted the drug concentrations obtained from pediatric patients. Furthermore, the final PBPK model showed good concordance with the known properties of bepotastine. Appropriate pediatric doses for different weight and age groups were proposed based on the simulations. Discrepancies in recommended doses from the two models were likely due to the incorporation of age-dependent physiological factors in the PBPK model. In conclusion, our study is the first to suggest an optimal oral dosing regimen of bepotastine in pediatric patients using both approaches. This is expected to foster safer and more productive use of the drug.
- 27 February 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (3) , 334
Open AccessPharmacokinetic Modeling of Bepotastine for Determination of Optimal Dosage Regimen in Pediatric Patients with Allergic Rhinitis or Urticaria
Bepotastine, a second-generation antihistamine for allergic rhinitis and urticaria, is widely used in all age groups but lacks appropriate dosing guidelines for pediatric patients, leading to off-label prescriptions. We conducted this study to propose an optimal dosing regimen for pediatric patients based on population pharmacokinetic (popPK) and physiologically based pharmacokinetic (PBPK) models using data from two previous trials. A popPK model was built using NONMEM software. A one-compartment model with first-order absorption and absorption lag time described our data well, with body weight incorporated as the only covariate. A PBPK model was developed using PK-Sim software version 10, and the model well predicted the drug concentrations obtained from pediatric patients. Furthermore, the final PBPK model showed good concordance with the known properties of bepotastine. Appropriate pediatric doses for different weight and age groups were proposed based on the simulations. Discrepancies in recommended doses from the two models were likely due to the incorporation of age-dependent physiological factors in the PBPK model. In conclusion, our study is the first to suggest an optimal oral dosing regimen of bepotastine in pediatric patients using both approaches. This is expected to foster safer and more productive use of the drug.
- Open Access
- 1 September 2021
- Published by Korean Society for Clinical Pharmacology and Therapeutics in Translational and Clinical Pharmacology
- Vol. 29 (3) , 150-159
Comparison of the pharmacokinetics and pharmacodynamics of YH4808 in healthy subjects for defining an appropriate dosing regimen
YH4808 is a novel potassium-competitive acid blocker developed for gastric acid-related disorders. Previous studies indicate its potential to improve symptoms of gastric acid-related disorders. The current study was aimed to find the optimal regimen of YH4808 for night time pH control. This study was performed in two parts. Each was a randomized, open-label, active-controlled, multiple-doses, two-treatment, two-period crossover study conducted in 20 healthy Korean volunteers. Subjects were randomly assigned to one of the four groups. The three groups received different dosage regimens of YH4808 (100 mg twice a day, 200 mg once a day, or 200 mg twice a day), and the fourth group received esomeprazole 40 mg twice a day. The pharmacokinetic parameters demonstrated that the systemic exposure of YH4808 increased in a dose-proportional manner. The difference in the proportion of time above pH 4 over 24 h from the baseline was the greatest in the group receiving YH4808 200 mg twice a day. The values of the area under the effect curve at night time (12 A.M.-7 A.M.) were higher in all YH4808 groups than in the esomeprazole group. However, the differences among the YH4808 groups were not statistically significant (p > 0.05). YH4808 exhibited potential for better pH control during the night in comparison to esomeprazole. The optimal regimen for night time pH control among all the YH4808 regimens was 200 mg twice a day.
- 1 September 2021
- Published by Korean Society for Clinical Pharmacology and Therapeutics in Translational and Clinical Pharmacology
- Vol. 29 (3) , 150-159
Open AccessComparison of the pharmacokinetics and pharmacodynamics of YH4808 in healthy subjects for defining an appropriate dosing regimen
YH4808 is a novel potassium-competitive acid blocker developed for gastric acid-related disorders. Previous studies indicate its potential to improve symptoms of gastric acid-related disorders. The current study was aimed to find the optimal regimen of YH4808 for night time pH control. This study was performed in two parts. Each was a randomized, open-label, active-controlled, multiple-doses, two-treatment, two-period crossover study conducted in 20 healthy Korean volunteers. Subjects were randomly assigned to one of the four groups. The three groups received different dosage regimens of YH4808 (100 mg twice a day, 200 mg once a day, or 200 mg twice a day), and the fourth group received esomeprazole 40 mg twice a day. The pharmacokinetic parameters demonstrated that the systemic exposure of YH4808 increased in a dose-proportional manner. The difference in the proportion of time above pH 4 over 24 h from the baseline was the greatest in the group receiving YH4808 200 mg twice a day. The values of the area under the effect curve at night time (12 A.M.-7 A.M.) were higher in all YH4808 groups than in the esomeprazole group. However, the differences among the YH4808 groups were not statistically significant (p > 0.05). YH4808 exhibited potential for better pH control during the night in comparison to esomeprazole. The optimal regimen for night time pH control among all the YH4808 regimens was 200 mg twice a day.
- Open Access
- 1 January 2020
- Published by Korean Society for Clinical Pharmacology and Therapeutics in Translational and Clinical Pharmacology
- Vol. 28 (3) , 136-146
Pharmacodynamic evaluation of YH4808 for Helicobacter pylori eradication in healthy subjects
Park H, et al. Transl Clin Pharmacol. 2020 Sep;28:e16. /Synapse/10.12793/tcp.2020.28.e16
- 1 January 2020
- Published by Korean Society for Clinical Pharmacology and Therapeutics in Translational and Clinical Pharmacology
- Vol. 28 (3) , 136-146
Open AccessPharmacodynamic evaluation of YH4808 for Helicobacter pylori eradication in healthy subjects
Park H, et al. Transl Clin Pharmacol. 2020 Sep;28:e16. /Synapse/10.12793/tcp.2020.28.e16
- Open Access
- 1 January 2020
- Published by Korean Society for Clinical Pharmacology and Therapeutics in Translational and Clinical Pharmacology
- Vol. 28 (1) , 55-65
Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects
Lee WY, et al. Transl Clin Pharmacol. 2020 Mar;28:e5. /Synapse/10.12793/tcp.2020.28.e5
- 1 January 2020
- Published by Korean Society for Clinical Pharmacology and Therapeutics in Translational and Clinical Pharmacology
- Vol. 28 (1) , 55-65
Open AccessEvaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects
Lee WY, et al. Transl Clin Pharmacol. 2020 Mar;28:e5. /Synapse/10.12793/tcp.2020.28.e5